CAPS

MARCH HARVARD CAPS / HARRIS POLL: TRUMP'S LEAD NARROWS TO 2 POINTS AFTER BIDEN GIVES STATE OF THE UNION

Retrieved on: 
Monday, March 25, 2024
Speech, Hamas, Union, Ronald Reagan, CAPS, The Harris Poll, Harvard University, Apple Podcasts, IHeartRadio, Radio, Trump, Public opinion, NOT, ByteDance, Stagwell, BAN

NEW YORK and CAMBRIDGE, Mass., March 25, 2024 /PRNewswire/ -- Stagwell (NASDAQ: STGW) today released the results of the March Harvard CAPS / Harris poll, a monthly collaboration between the Center for American Political Studies at Harvard (CAPS) and the Harris Poll and HarrisX.

Key Points: 
  • President Joe Biden's overall approval rating remained at 45%, while 55% of voters say they approve of Donald Trump's job as president.
  • Trump is leading Biden by 2 points in the general head-to-head, down from 6 points last month.
  • The March Harvard CAPS / Harris poll survey was conducted online within the United States on March 20-21, 2024, among 2,111 registered voters by The Harris Poll and HarrisX.
  • Follow the Harvard CAPS Harris Poll podcast at https://www.markpennpolls.com/ or on iHeart Radio, Apple Podcasts, Spotify, and other podcast platforms.

BetterMynd Accelerates Student Impact, Now Serving More Than 100 College and University Partners To Deliver High Quality Online Student Mental Health Support

Retrieved on: 
Thursday, March 14, 2024
Online, BIPOC, Psychological Services, Growth, Achievement Medal, Psychiatry, CAPS, University of Nebraska–Lincoln, Mental, Philosophy, Partnership, Mental health, University, Doctor of Philosophy, Student, Medication, Success, Senior counsel, Counselor, Nursing

BUFFALO, N.Y., March 14, 2024 /PRNewswire-PRWeb/ -- BetterMynd, a leading online therapy platform that centers on the mental health needs of college students and the college and university counseling centers that serve them, announced today that it has significantly accelerated its growth, including a 66% year-over-year growth in campus partnerships and a 1.9x year-over-year growth in 50-minute online therapy sessions held. With 77% of students on college campuses experiencing mental health challenges and more than 85% of college counseling centers experiencing increased demand for online therapy, providing more accessible and personalized care to students to meet their unique mental health needs has never been more important.

Key Points: 
  • This increase in successful sessions is key to meeting the 60% increased demand for mental health services among college students.
  • Growth in Partner Campuses: BetterMynd experienced a 66% growth in partnerships from February 2023 to February 2024, welcoming an additional 47 partners.
  • In 2024 alone, the company welcomed five new partners, including University of Nebraska-Lincoln and Southern University and A&M College System.
  • BetterMynd supplements and expands on-campus mental health resources by providing students access to 50-minute individual counseling sessions online from the company's diverse network of over 400 licensed and insured mental health clinicians.

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Retrieved on: 
Monday, March 11, 2024
SAN, Ulcerative colitis, Week, CDAI, IC50, Solipsism syndrome, Peripheral, Obesity, Cerebrospinal fluid, Cardiovascular disease, Treatment, MACE, NLRP3, Volunteering, Inflammation, Modulation, QD, Safety, Biomarker, UC, CAPS, Pharmacokinetics, Webcast, Patient, Molina Healthcare, TYK2, CSF, PIPE, Plasma, FCAS, Risk, Pharmaceutical industry

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates today during its virtual investor event.

Key Points: 
  • We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
  • We believe these data establish compelling clinical proof of concept for our peripheral NLRP3 inhibitor VTX2735.
  • At our virtual investor event, we will present data from the ongoing Phase 2 open-label extension.
  • Ventyx will host a virtual investor event today, Monday, March 11, 2024 from 11:00AM to 12:30PM ET.

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

Retrieved on: 
Monday, March 4, 2024
SAN, Ulcerative colitis, NLRP3, CAPS, Webcast, Inflammation, Pharmaceutical industry

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host a virtual investor event on Monday, March 11, 2024 from 11:00 a.m. to 12:30 p.m.

Key Points: 
  • SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host a virtual investor event on Monday, March 11, 2024 from 11:00 a.m. to 12:30 p.m.
  • We will also provide a clinical update from the ongoing open-label extension of the VTX002 Phase 2 trial in ulcerative colitis.
  • To participate in the event, please dial (800) 343-4849 (U.S.) or (203) 518-9848 (international) and reference passcode VTYX0311.
  • A live webcast will be available in the Investors section of the Company’s website at www.ventyxbio.com .

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Tuesday, February 27, 2024
SAN, Ulcerative colitis, Quarter, Week, CDAI, Peripheral, Blood, Obesity, ALS, Research and development, Cryopyrin-associated periodic syndrome, NLRP3, Volunteering, Inflammation, Modulation, Multiple sclerosis, Rheumatology, Safety, UC, CAPS, CNS, Administration, Pharmacokinetics, Patient, TYK2, FCAS, G&A, Ulcer, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $252.2 million as of December 31, 2023.
  • Research and Development (R&D) expenses: R&D expenses were $42.0 million for the fourth quarter of 2023, compared to $30.2 million for the fourth quarter of 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the fourth quarter of 2023, compared to $8.4 million for the fourth quarter of 2022.
  • Net loss: Net loss was $46.8 million for the fourth quarter of 2023, compared to $35.2 million for the fourth quarter of 2022.

EudraVigilance - EVWEB user manual

Retrieved on: 
Sunday, March 10, 2024
International Organization (journal), Level 2, Automation, Chapter Two, ACK, ISO, Classification, SSL, Sender, Clinical trial, Radio, Immediate, European, CAPS, European Medicines Agency, Report, MDN, ICH, Medicine, HTML, Internet, Medical dictionary, NCA, Originality, HTTPS, SHTTP, European Economic Area, Headquarters, NASK, Three-body problem, Privacy, Match, Database, Data entry, European Economic Community, MSSO, Module, ZIP, Acknowledgment, Acronym, Environment, Message, MLM, Access, Conference, Pharmacovigilance, XML, EMA, Gateway, Chapter One, MedDRA, Active ingredient, Communication, Validation, Public, Data analysis, Precision, RTF, Navigation, Salt, Security, Chapter Five, Contextual, International organization, Convention, SME, URL, Chapter Four, ID, MAH, Rich Text Format, Microsoft Edge, EudraVigilance, Name, MSK, UNK, Risk, Create, Tree view, ICSR, Chapter Three, Web browser, Commercial, R2, Socs, TAB, Literature, Courier, CIOMS, EV, Built-in self-test, Documentation, Coreidae, Council, S-HTTP, File Explorer, UI, Import, Calendar, WEB, Reproduction, Jousting, PDF, Economic union, Mobile phone
Key Points: 

    FEBRUARY HARVARD CAPS / HARRIS POLL: IMMIGRATION REMAINS TOP ISSUE AS VOTERS SAY BIDEN'S BIGGEST FAILURE IS HIS OPEN BORDERS POLICY

    Retrieved on: 
    Monday, February 26, 2024
    Special counsel, Trump, Public opinion, Harvard University, The Harris Poll, Democrat, Plasma protein binding, Homeland security, CAPS, Policy, Apple Podcasts, Radio, Stagwell, Senate, IHeartRadio

    NEW YORK and CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- Stagwell (NASDAQ: STGW) today released the results of the February Harvard CAPS / Harris poll, a monthly collaboration between the Center for American Political Studies at Harvard (CAPS) and the Harris Poll and HarrisX.

    Key Points: 
    • Immigration and inflation are the top two issues for voters for the second month in a row.
    • Voters say Biden's biggest failure was creating an open borders policy and a historic flood of immigrants.
    • The February Harvard CAPS / Harris poll survey was conducted online within the United States on February 21-22, 2024, among 2,022 registered voters by The Harris Poll and HarrisX.
    • Follow the Harvard CAPS Harris Poll podcast at https://www.markpennpolls.com/ or on iHeart Radio, Apple Podcasts, Spotify, and other podcast platforms.

    CAN TV Announces Five New Board Members

    Retrieved on: 
    Tuesday, February 20, 2024
    SVKM's NMIMS, Robak, Sierra Club, Television, Workplace, BBU, Marketing, CAN TV, News, Growth, Communication, Kellogg School, Diversity, Human, CAPS, Water, Equity, Associate, Chicago Public Media, State, Bimbo Bakeries USA, Environment, CARE, Management

    CHICAGO, Feb. 20, 2024 /PRNewswire/ -- CAN TV , Chicago's premiere hub for community access news, hyperlocal stories and educational resources, is pleased to announce five new members to its Board of Directors.

    Key Points: 
    • CHICAGO, Feb. 20, 2024 /PRNewswire/ -- CAN TV , Chicago's premiere hub for community access news, hyperlocal stories and educational resources, is pleased to announce five new members to its Board of Directors.
    • The five new board members include:
      "It has been incredible to spearhead and witness firsthand the efforts CAN TV is taking to deepen its connection with Chicagoans, an important aspect of our overall mission.
    • Our new board members will provide expanded leadership capacity, and fresh perspectives that will exponentially grow our capacity to fulfill our critical mission," said Darrious Hilmon, Executive Director of CAN TV.
    • "CAN TV's Board and Leadership team are in lock-step, fully committed to ensuring a strong future for the network," said CAN TV's Board Chair Anna Ninoyu.

    Big Blue Marble Academy Announces the Opening of Its 70th Location

    Retrieved on: 
    Friday, February 16, 2024
    Curriculum, CAPS, Infant, Education, Learning, Toy

    Big Blue Marble Academy Powder Springs marks the 70th overall location of the leading early childhood educator and the 27th center in Georgia.

    Key Points: 
    • Big Blue Marble Academy Powder Springs marks the 70th overall location of the leading early childhood educator and the 27th center in Georgia.
    • With the mission to Nurture Little Minds and Grow Big Hearts, Big Blue Marble Academy Powder Springs offers the best in early childhood care, enriching curriculum, and play development.
    • As experts in early childhood education, Big Blue Marble Academy understands the significance of providing a well-rounded curriculum that goes beyond the basics.
    • "This is a special opening as we celebrate our 70th Big Blue Marble Academy location," said Jeff Wahl, CEO of Big Blue Marble Academy.

    HealthRules® Payer Named “Best in KLAS” for Third Consecutive Year in 2024

    Retrieved on: 
    Wednesday, February 7, 2024
    Practice Management, Technology, Professional Services, Health, Payments, Health Technology, Health Insurance, Software, Artificial Intelligence, Internet, Insurance, Partnership, CAPS, COVID-19, Research, AI, EVP, Automation, Human, Organization, Movement, Online shopping

    “’Best in KLAS’ is validation that HealthRules Payer is delivering business value and an exceptional experience to leading health plans,” said Anshul Pande, EVP and General Manager HealthRules Payer.

    Key Points: 
    • “’Best in KLAS’ is validation that HealthRules Payer is delivering business value and an exceptional experience to leading health plans,” said Anshul Pande, EVP and General Manager HealthRules Payer.
    • “We partner with our customers on their digital transformation journeys, and their input guides how we innovate with our cloud-based solutions, including investment in AI and enhanced automation.
    • Insights from the KLAS research showed several notable trends among HealthRules Payer customers beyond the #1 ranking in the category.
    • “The voice of our customers is vital to our focus on continuous improvement in our company and our product.